Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec

Date
2017
Author
Soysal, Teoman
Eskazan, Ahmet Emre
Sadri, Sevil
Ayer, Mesut
Kantarcioglu, Bulent
Demirel, Naciye
Aydin, Demet
Aydinli, Fuat
Yokus, Osman
Tuzuner, Nukhet
Ozunal, Isil Erdogan
Yalniz, Fevzi Firat
Keskin, Dilek
Aydin, Yildiz
Ar, Muhlis Cem
Elverdi, Tugrul
Berk, Selin
Ongoren, Seniz
Salihoglu, Ayse
Baslar, Zafer
Ozbek, Ugur
Metadata
Show full item record
Abstract
We retrospectively evaluated 90 patients with chronic myeloid leukemia receiving either upfront original imatinib (Ol) or generic imatinib (Gl) for the effect of the early molecular response on the long-term outcome. We demonstrated that achieving an optimal response at 3 and 6 months in patients receiving either first-line Gl or Ol was clearly associated with greater response and event-free survival rates.
URI
http://hdl.handle.net/20.500.12627/141684
https://doi.org/10.1016/j.clml.2017.07.255
Collections